E. Di Bartolomeo, “Once-daily intravenous busulfan as myeloablative, reduced-toxicity conditioning regimen: results in young and adult patients with hematological malignant and nonmalignant diseases”, Hematol Meeting Rep, vol. 2, no. 6, Jun. 2009.